Cyclosporine for the treatment of feline allergic skin diseases by Favrot, C
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Cyclosporine for the treatment of feline allergic skin diseases
Favrot, C
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-87435
Originally published at:
Favrot, C (2013). Cyclosporine for the treatment of feline allergic skin diseases. In: ESVD-ECVD Annual
Meeting, Valencia, Spain, 19 September 2013 - 21 September 2013.
Cyclosporine therapy for feline hypersensitivity dermatitis 
Claude Favrot 
Dermatology Service, Vetsuisse Faculty, University of Zurich, Zurich, 
Switzerland 
 
Cyclosporine A (CsA) is an immunomodulatory drug belonging to the group of 
calcineurin inhibitors. This lipophilic drug penetrates easily the cell membranes and 
binds in the cytoplasm to cyclophiline. CsA-Cyclophiline complex inihibits calcineurin, 
leading to an impaired activation of Nuclear Factor of Activated T cells (NF-AT). As 
NF-AT is one of the major activator of cytokine genes transcription, CsA 
administration results in an impaired expression of cytokines.  
At the cellular level, CsA inhibits T lymphocyte activation, eosinophil recruitement, 
functions and growth of antigen-presenting cells, especially Langerhans cells, pro 
inflammatory cytokines secretion of keratinocytes and IgE mediated mast cell 
degranulation. 
After oral or intravenous administration, peak and trough levels are highly variable in 
cats. It has however been shown that serum concentration and clinical efficacy are 
not correlated which implies that routine evaluation of CsA blood concentration is not 
necessary, in most occasions. The peak concentration is obtained one hour after oral 
administration of 5mg/kg CsA and ranges between 100 and 1600 ng/ml when 
measured by high-pressure liquid chromatography. It is worth noticing that CsA 
values depend on the technique used and immunoassays provided usually much 
higher values, when compared with high pressure chromatography. 
The bioavailability of CsA in cats is rather low (29%) and bioaccumulation is usually 
not observed. As mentioned above, CsA is a very lipophilic drug, which explains the 
high volume of distribution (6L/kg) as well as the high concentration in the skin (4 
times higher than in serum). Feeding before CsA administration is associated with a 
lower bioavailability but this decrease does not seem to impair clinical outcomes.  
CsA interacts with cytochrome P 450 3A4 and drug interactions are consequently 
numerous. Very few have however been demonstrated in clinical study and these 
interactions may be influenced by several factors such as age, concurrent diseases, 
dosage etc…  In cats, interaction between CsA and ketoconazole, itraconazole and 
clarythromycine have been demonstrated. Concomitant treatment should be 
associated with a reduction of CsA administration. Other possible interaction with 
ranitidine, omperazole, cimetidine, metoclopramine, allopurinol, erythromycin, 
digoxine, furosemide, ciprofloxacine, verapamil and trimethoprim- sulfa are likely. 
Side-effects of CsA include gastrointestinal signs, anorexia, weight loss and 
gingivitis. Otitis and cystitis are also sometimes observed during CsA treatmenteven 
though causality is not firmly established 1,2. Outdoor cats should also be tested for 
toxoplasma IgG before treatment and negative cats should not be treated or should 
be kept indoors during the whole treatment. On the contrary, IgG positive cats are 
protected. As well, cats with chronic infectious diseases such as FIV, FeLV, 
dermatophytosis should not be treated with CsA. Cats with chronic kidney deficiency 
and diabetes mellitus could treated with CsA but should be monitored carefully. 
In a Novartis intern study (freedom of information), cats were first vaccinated and, 
then, treated 4 months afterwards with CsA 24mg/kg during 8 weeks. These cats 
were subsequently re-vaccinated after this period of treatment: Titers were lower than 
in the control group but still in normal range which suggests that booster vaccination 
could be made during CsA treatment. 
The first evidence for the efficacy of CsA for the treatment of hypersensitivity cats 
was provided by an open study published by Noli and coworkers 3. The first 
controlled study was published by Wisselink and coworkers who compared two 
groups of allergic cats, the first one being treated with CSA 5 mg/kg and the second 
one with Prednisolone 0.5mg/kg. Improvement of the clinical signs were seen in both 
groups 4. Larger studies were published afterwards and evidence was provided that 
the better dosage for allergic cats was 7 mg/kg 2. Some other studies were carried 
out afterwards but are still not published. It was however demonstrated that after an 
initial phase of treatment of 6 to 8 weeks, about 70% of allergic cats only need every 
other day treatment. After 4 additional weeks, 55 % were treated only twice a week 
while 20 % were still on every other day treatement and 15% on daily administration. 
Only 10% did not respond to the treatment. 
All in all, studies show that CsA is a good treatment option for allergic cats and that 
most of them support the treatment well. 
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